DREAMM Data Sets GSK’s Blenrep Up For Second Line Myeloma Dominance
Overall survival data presented at ASH and filed with the US FDA puts Blenrep on course for a comeback – something that GSK’s oncology leader said he had never really doubted.
Overall survival data presented at ASH and filed with the US FDA puts Blenrep on course for a comeback – something that GSK’s oncology leader said he had never really doubted.